ES2073777T3 - Inhibicion de la replicacion virica. - Google Patents

Inhibicion de la replicacion virica.

Info

Publication number
ES2073777T3
ES2073777T3 ES91919581T ES91919581T ES2073777T3 ES 2073777 T3 ES2073777 T3 ES 2073777T3 ES 91919581 T ES91919581 T ES 91919581T ES 91919581 T ES91919581 T ES 91919581T ES 2073777 T3 ES2073777 T3 ES 2073777T3
Authority
ES
Spain
Prior art keywords
inhibition
viral replication
dna
cell
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919581T
Other languages
English (en)
Inventor
Michael J Scolaro
Sean M Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestar Inc filed Critical Vestar Inc
Application granted granted Critical
Publication of ES2073777T3 publication Critical patent/ES2073777T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL SUMINISTRO INTRACELULAR DE UN OLIGONUCLEOTIDO DE ADN CON LA MISMA SECUENCIA QUE UNA CEPA DE ORIGEN VIRAL QUE CODIFICA AL ADN QUE CODIFICA LA PRODUCCION DE UNA PROTEINA REGULADORA VIRAL INHIBE LA REPRODUCCION, EN UNA CELULA, DE UN VIRUS CON UN GENOMA QUE SE INTEGRA EN EL ADN HUESPED DE LA CELULA.
ES91919581T 1990-10-09 1991-10-09 Inhibicion de la replicacion virica. Expired - Lifetime ES2073777T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59525390A 1990-10-09 1990-10-09

Publications (1)

Publication Number Publication Date
ES2073777T3 true ES2073777T3 (es) 1995-08-16

Family

ID=24382446

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919581T Expired - Lifetime ES2073777T3 (es) 1990-10-09 1991-10-09 Inhibicion de la replicacion virica.

Country Status (9)

Country Link
EP (1) EP0552280B1 (es)
JP (1) JPH06504429A (es)
AT (1) ATE124457T1 (es)
AU (1) AU652006B2 (es)
CA (1) CA2093816A1 (es)
DE (1) DE69110897T2 (es)
DK (1) DK0552280T3 (es)
ES (1) ES2073777T3 (es)
WO (1) WO1992006192A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
EP0734251B1 (en) * 1993-12-17 2009-10-14 Novavax, Inc. Method of transmitting a biologically active material to a cell
JP4259611B2 (ja) * 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
IL160080A0 (en) 2001-08-31 2004-06-20 Thomson Licensing Sa Sequence counter for an audio visual stream
WO2005027979A2 (en) * 2003-09-17 2005-03-31 Let There Be Hope Medical Research Institute Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853139T2 (de) * 1987-06-26 1995-06-14 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
DE3742049A1 (de) * 1987-12-11 1989-06-22 Theurer Karl Eugen Herstellung und anwendung von impfstoffen und diagnostika fuer virus- und krebserkrankungen
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides

Also Published As

Publication number Publication date
JPH06504429A (ja) 1994-05-26
EP0552280B1 (en) 1995-06-28
CA2093816A1 (en) 1992-04-10
DE69110897D1 (de) 1995-08-03
EP0552280A1 (en) 1993-07-28
AU8875991A (en) 1992-04-28
WO1992006192A1 (en) 1992-04-16
ATE124457T1 (de) 1995-07-15
AU652006B2 (en) 1994-08-11
DK0552280T3 (da) 1995-08-28
DE69110897T2 (de) 1995-11-30

Similar Documents

Publication Publication Date Title
DE69535125D1 (de) Impstoff gegen felines immunodefizienz-virus
ATE273320T1 (de) Fusogene liposomen
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
DK0870046T3 (da) Levende rekombinant vaccine som indeholder felint herpesvirus type 1, især til behandling af felin infektiös peritonitis
ES2073777T3 (es) Inhibicion de la replicacion virica.
DE60126933D1 (de) Verfahren zur fermentativen herstellung von l-threonine
FI905848A (fi) Tryckvaetskemekanism, saosom motor eller pump, som aer kopplad till ett bromsorgan.
DE69230535T2 (de) Polyphenol oxidase gene
DE68911297D1 (de) Heparin bindende proteine, dafür kodierende dna, verfahren zu ihrer herstellung sowie sie enthaltende therapeutische präparate.
AU2001279581A1 (en) Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
AU686000B2 (en) Infectious peritonitis vaccine
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE356144T1 (de) Regulatorische/entfaltende peptide von ezrin
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
DE50304603D1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
WO2000042063A3 (de) Peptide zur inhibierung von hbv-core-proteinen
EE200100234A (et) PRV-1-geen ja selle kasutamine
AU1557001A (en) Novel endoplasmic reticulum-localized protein, remedies containing the same for diseases associated with glycoprotein abnormality, dna encoding this protein andgene remedies containing the same for treating diseases associated with glycopr otein abnormality
ES2084587T3 (es) Arn virus no revertientes.
FI890231A (fi) Çkaerlekssigillç, aer ett çlaosç som laoses antingen med verktyg eller foer hand, men som inte kan upplaoses utan att den gaor soender.
ATE98261T1 (de) Heparin bindende proteine, dafuer kodierende dna, verfahren zu ihrer herstellung sowie sie enthaltende therapeutische praeparate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552280

Country of ref document: ES